Clinical and Immunologic Profiles in Incomplete Lupus Erythematosus and Improvement with Hydroxychloroquine Treatment

Autoimmune Diseases

Volumn 2016, Issue , 2016, Pages

  Olsen, Nancy J ^a   McAloose, Carl ^a   Carter, Jamie ^a   Han, Bobby Kwanghoon ^b   Raman, Indu ^c   Li, Quan Zhen ^c   Liao, Duanping ^d  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; HYDROXYCHLOROQUINE; INTERFERON; MACROPHAGE DERIVED CHEMOKINE;

ADULT; ARTICLE; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; FEMALE; GENE EXPRESSION; HEALTH STATUS; HUMAN; INCOMPLETE LUPUS ERYTHEMATOSUS; LUPUS ERYTHEMATOSUS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PATIENT-REPORTED OUTCOME; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE;

EID: 85009375029     PISSN: 20900422     EISSN: 20900430     Source Type: Journal    
DOI: 10.1155/2016/8791629     Document Type: Article

References (31)

1. J. M. Greer, R. S. Panush, "Incomplete lupus erythematosus, " Archives of Internal Medicine, vol. 149, no. 11, pp. 2473-2476, 1989.
2. L. M. Vilá, A. M. Mayor, A. H. Valentn, M. Garcá-Soberal, S. Vilá, "Clinical outcome, predictors of disease evolution in patients with incomplete lupus erythematosus, " Lupus, vol. 9, no. 2, pp. 110-115, 2000.
3. I. T. Wieczorek, K. J. Propert, J. Okawa, V. P. Werth, "Systemic symptoms in the progression of cutaneous to systemic lupus erythematosus, " JAMA Dermatology, vol. 150, no. 3, pp. 291-296, 2014.
4. M. F. Ugarte-Gil andG. S. Alarcón, "Incomplete systemic lupus erythematosus: early diagnosis or overdiagnosis" Arthritis Care & Research, vol. 68, no. 3, pp. 285-287, 2016.
5. K. H. Costenbader, P. H. Schur, "We need better classification, terminology for 'people at high risk of or in the process of developing lupus', " Arthritis Care, Research, vol. 67, no. 5, pp. 593-596, 2015.
6. M. C. Hochberg, "Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus, " Arthritis, Rheumatism, vol. 40, no. 9, p. 1725, 1997.
7. M. Petri, A.-M. Orbai, G. S. Alarcón et al. , "Derivation, validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus, " Arthritis, Rheumatism, vol. 64, no. 8, pp. 2677-2686, 2012.
8. A. E. Wandstrat, F. Carr-Johnson, V. Branch et al. , "Autoantibody profiling to identify individuals at risk for systemic lupus erythematosus, " Journal of Autoimmunity, vol. 27, no. 3, pp. 153-160, 2006.
9. T. Pincus, "Amultidimensional health assessment questionnaire (MDHAQ) for all patients with rheumatic diseases to complete at all visits in standard clinical care, " Bulletin of theNYUHospital for Joint Diseases, vol. 65, no. 2, pp. 150-160, 2007.
10. H. Zhu, W. Mi, H. Luo et al. , "Whole-genome transcription, DNA methylation analysis of peripheral blood mononuclear cells identified aberrant gene regulation pathways in systemic lupus erythematosus, " Arthritis Research & Therapy, vol. 18, no. 1, article 162, 2016.
11. N. J. Olsen, C. F. Spurlock III, T. M. Aune, "Methotrexate induces production of IL-1, IL-6 in the monocytic cell line U937, " Arthritis Research, Therapy, vol. 16, no. 1, article R17, 2014.
12. L. Inês, C. Silva, M. Galindo et al. , "Classification of systemic lupus erythematosus: Systemic Lupus International Collaborating Clinics versus American College of Rheumatology criteria. A comparative study of 2, 055 patients from a real-life, international systemic lupus erythematosus cohort, " Arthritis Care, Research, vol. 67, no. 8, pp. 1180-1185, 2015.
13. Q.-Z. Li, J. Zhou, Y. Lian et al. , "Interferon signature gene expression is correlated with autoantibody profiles in patients with incomplete lupus syndromes, " Clinical, Experimental Immunology, vol. 159, no. 3, pp. 281-291, 2010.
14. A.-M. Orbai, L. Truedsson, G. Sturfelt et al. , "Anti-C1q antibodies in systemic lupus erythematosus, " Lupus, vol. 24, no. 1, pp. 42-49, 2015.
15. M. Y. Choi, M. R. Barber, C. E. Barber, A. E. Clarke, M. J. Fritzler, "Preventing the development of SLE: identifying risk factors, proposing pathways for clinical care, " Lupus, vol. 25, no. 8, pp. 838-849, 2016.
16. A. R. Fonseca, M. I. C. Gaspar-Elsas, M. G. P. Land, S. K. F. de Oliveira, "Comparison between three systems of classification criteria in juvenile systemic lupus erythematous, " Rheumatology, vol. 54, no. 2, pp. 241-247, 2015.
17. M. Al Daabil, E. M. Massarotti, A. Fine et al. , "Development of SLE among "potential SLE" patients seen in consultation: longterm follow-up, " International Journal of Clinical Practice, vol. 68, no. 12, pp. 1508-1513, 2014.
18. N. J. Olsen, M. Yousif, A. Mutwally, M. Cory, N. Elmagboul, D. R. Karp, "Organ damage in high-risk patients with systemic, incomplete lupus syndromes, " Rheumatology International, vol. 33, no. 10, pp. 2585-2590, 2013.
19. G. K. Bertsias, C. Pamfil, A. Fanouriakis, D. T. Boumpas, "Diagnostic criteria for systemic lupus erythematosus: has the time come" Nature Reviews Rheumatology, vol. 9, no. 11, pp. 687-694, 2013.
20. N. J. Olsen, Q.-Z. Li, J. Quan, L. Wang, A. Mutwally, D. R. Karp, "Autoantibody profiling to follow evolution of lupus syndromes, " Arthritis Research andTherapy, vol. 14, no. 4, article no. R174, 2012.
21. J. M. Ahearn, C.-C. Liu, A. H. Kao, S. Manzi, "Biomarkers for systemic lupus erythematosus, " Translational Research, vol. 159, no. 4, pp. 326-342, 2012.
22. R. Lu, M. E. Munroe, J. M. Guthridge et al. , "Dysregulation of innate, adaptive serum mediators precedes systemic lupus erythematosus classification, improves prognostic accuracy of autoantibodies, " Journal of Autoimmunity, vol. 74, pp. 182-193, 2016.
23. I. R. Cohen, C. Putterman, N. Jordan et al. , "SLE-key rule-out serologic test for SLE using the immunarray ICHIP, " Annals of the Rheumatic Diseases, vol. 74, 2015.
24. C. Eriksson, S. Rantapaä-Dahlqvist, "Cytokines in relation to autoantibodies before onset of symptoms for systemic lupus erythematosus, " Lupus, vol. 23, no. 7, pp. 691-696, 2014.
25. E. S. Robinson, V. P. Werth, "The role of cytokines in the pathogenesis of cutaneous lupus erythematosus, " Cytokine, vol. 73, no. 2, pp. 326-334, 2015.
26. H.-F. Pan, R.-X. Leng, X.-P. Li, S. G. Zheng, D.-Q. Ye, "Targeting T-helper 9 cells, interleukin-9 in autoimmune diseases, " Cytokine, Growth Factor Reviews, vol. 24, no. 6, pp. 515-522, 2013.
27. K. E. Graeber, N. J. Olsen, "Th17 cell cytokine secretion profile in host defense, autoimmunity, " Inflammation Research, vol. 61, no. 2, pp. 87-96, 2012.
28. K. Sacre, L. A. Criswell, J. M. McCune, "Hydroxychloroquine is associated with impaired interferon-alpha, tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus, " Arthritis Research, Therapy, vol. 14, no. 3, article R155, 2012.
29. R. M. Clancy, A. J. Markham, J. P. Buyon, "Endosomal Toll-like receptors in clinically overt, silent autoimmunity, " Immunological Reviews, vol. 269, no. 1, pp. 76-84, 2016.
30. R. Willis, A. M. Seif, G. McGwin Jr. et al. , "Effect of hydroxychloroquine treatment on pro-inflammatory cytokines, disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort, " Lupus, vol. 21, no. 8, pp. 830-835, 2012.
31. K. C. Kalunian, "Interferon-targeted therapy in systemic lupus erythematosus: is this an alternative to targeting B, T cells" Lupus, vol. 25, no. 10, pp. 1097-1101, 2016.